After passing a multilateral expertise, Dipiaron received venture investment from the PharmMed Innovations fund managed by Unicorn Capital Partners LLC (www.unicpartners.com).
The company will receive investments in the amount sufficient to conduct phase I and phase II clinical trials. In accordanse to the investment plan Dipiaron LLC has started preparing a package of documents required for phase I clinical trial approval and manufacturing of clinical batches.